<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00143</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=21 g=1 f=1 --> I accept this recommendation, and Appendix L, Regarding Release into the  <!-- PJG 0012 frnewline --> Environment, of the NIH Guidelines will be deleted accordingly.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> II. Summary of Actions  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. Amendment to Appendix M&hyph;I&hyph;D of the NIH Guidelines Regarding Informed  <!-- PJG 0012 frnewline --> Consent for Human Gene Transfer Protocols  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;D will read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> Appendix M&hyph;I&hyph;D. Informed Consent  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> In accordance with the requirements of DHHS regulations for the Protection of Human Subjects (45 CFR Part 46), investigators should indicate how subjects will be informed about the proposed study and the manner in which their consent will be solicited. They should also indicate how the Informed Consent document makes clear the special requirements of gene transfer research.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;1. Communication About the Study to Potential Participants  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;a <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Which members of the research group and/or institution will be responsible for contacting potential participants and for describing the  <!-- PJG 0012 frnewline --> study to them? What procedures will be used to avoid possible conflicts of  <!-- PJG 0012 frnewline --> interest if the investigator is also providing medical care to potential subjects?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;b <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> How will the major points covered in Appendices M&hyph;I&hyph;A through M&hyph;I&hyph;C be disclosed to potential participants and/or their parents or guardians in language that is understandable to them?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;c <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> What is the length of time that potential participants will have to make a decision about their participation in the study?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;1&hyph;d <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> If the study involves pediatric or mentally handicapped subjects, how will the assent of each person be obtained?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=73 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2. Informed Consent Document  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``Investigators submitting human gene transfer proposals for Recombinant DNA Advisory Committee review must include the Informed Consent document as  <!-- PJG 0012 frnewline --> approved by the local Institutional Review Boards. A separate Informed Consent document should be used for the gene transfer portion of a research project when gene transfer is used as an adjunct in the study of another technique, e.g., when a gene is used as a `marker' or to enhance the power of immunotherapy for cancer.  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            